Effect of Comprehensive Geriatric Assessment on Short-time Mortality in Elderly Cancer Patients
NCT ID: NCT03814213
Last Updated: 2019-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
781 participants
OBSERVATIONAL
2019-01-16
2019-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients recieving CGA is part of a Randomised controlled study (ID: NCT02837679) comparing CGA without 90 days follow-up to CGA with 90 days of Comprehensive geriatric care.
Patients are identified from electronic medical files. Data regarding death is obtained from Medical files.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Suitability of an Organization With an Onco-geriatric Team to a Whole Region (Region Midt) of Denmark
NCT02072733
Understanding Needs of Older Patients Prior to Starting Cancer Treatment
NCT07225920
Geriatric and Oncologic Assessment Before Treatment
NCT02671994
Nutritional Intervention in Geriatric Oncology
NCT00459589
Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer
NCT02517034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* 70 years or more
* Cancer of the head and neck (HNC), lung (LC), upper gastro-intestinal- tract (UGI) or colo-rectal cancer (CRC)
* Referred to the Outpatient Clinic at department of oncology at Aarhus University Hospital for cancer treatment.
* Living in Aarhus, Favrskov, Odder or Skanderborg Municipalities
Exclusion:
\- Referred for specialised palliative care
Patients with both newly diagnosed cancer disease and patients with a relapse of previously treated cancer disease are included. Patients qualify for participation regardless of the stage of the cancer disease and regardless if specific cancer treatment is initiated.
The oncology department is responsible for identifying patients and informing of the planned CGA.
All potential patients referred to the oncology outpatient clinic are identified by retrospective review of lists of planned consultations in the oncology department out patient clinic available in the electronic medical file approximately once a week. By this procedure patients who were not informed of the possibility of having a CGA are identified (Group1) Patients who are referred for geriatric evaluation have a complete CGA at baseline. The CGA comprises 7 instruments for assessing health: Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) for autonomy, Mini Nutritional Status (MNA) for nutritional state, Mini Mental State Examination (MMSE) for Cognitive state, Geriatric Depression Scale 15-item (GDS) for mood and Cumulative Illness Rating Scale - Geriatrics (CIRS-G) for comorbidity and number of daily medication for polypharmacy as previously published. According to CGA, patients were given a CGA-status of "fit", "vulnerable" or "frail". In order to be "fit" all of the following should be present: Independence in ADL and IADL, less than 5 daily medications, no severe comorbidity and no more than 2 well controlled comorbidities, normal cognitive ability and no indications of depression or malnutrition. Information on whether or not the multidisciplinary team initiated any individual action/advice based on the CGA in group 1 and group 2 was registered as well. Interventions initiated by the multidisciplinary team were recorded in four categories: medical changes, nutritional intervention, physical intervention or social intervention. These interventions were registered before randomization was performed Frail and vulnerable patients are offered participation in a controlled randomized study (Clinical trialsID: NCT02837679). Patients are randomly and 1:1 assigned to either: No tailored follow-up (Group 2) or 90 days tailored follow up (group 3). Randomization were performed by REDcap and allocated equally by CGA-status (frail/vulnerable), gender and index tumor site (CRC or no-CRC).
It is not possible to blind patients or the multidisciplinary team of the randomization.
Group 2 has no tailored follow up on the problems found during CGA. Group 3 has 90 days tailored follow-up on problems that were identified during CGA and problems that evolved during the follow-up period.
Tailored follow-up The tailored intervention consists of phone calls, home visits, or contact to community care-takers. A multidisciplinary team consisting of a trained geriatric nurse and a geriatrician specialist performs the follow up. The team can perform clinical investigation of patients, initiate changes in medication, or referral to further investigation. Furthermore transfusion of blood, fluids or i.v. antibiotics could be performed either at home or in the geriatric out patient clinic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No-CGA
Patients were not initially offered CGA due to no booking for CGA
No interventions assigned to this group
CGA alone
Patients had CGA, but no tailored follow-up upon identified problems
CGA
Multi-level Health assessment
CGA with tailored care
CGA and a tailored follow-up and care for 90 days following the CGA
CGA
Multi-level Health assessment
tailored care
Tailored care based on problems identified by CGA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CGA
Multi-level Health assessment
tailored care
Tailored care based on problems identified by CGA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\-
Exclusion Criteria
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Cancer Society
OTHER
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marianne Ørum
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Else M Damsgaard, DMsc
Role: STUDY_CHAIR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geriatric Department Aarhus University Hospital
Aarhus, , Denmark
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
90-days mortality
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.